JP2014515258A - 免疫調節活性を有する細胞集団、その調製方法、及び、その使用 - Google Patents

免疫調節活性を有する細胞集団、その調製方法、及び、その使用 Download PDF

Info

Publication number
JP2014515258A
JP2014515258A JP2014510832A JP2014510832A JP2014515258A JP 2014515258 A JP2014515258 A JP 2014515258A JP 2014510832 A JP2014510832 A JP 2014510832A JP 2014510832 A JP2014510832 A JP 2014510832A JP 2014515258 A JP2014515258 A JP 2014515258A
Authority
JP
Japan
Prior art keywords
cells
cell
cell population
immunoregulatory
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014510832A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515258A5 (enExample
Inventor
デ ラ ローサ オルガ
Original Assignee
ティゲニックス エス．エー．ユー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ティゲニックス エス．エー．ユー filed Critical ティゲニックス エス．エー．ユー
Publication of JP2014515258A publication Critical patent/JP2014515258A/ja
Publication of JP2014515258A5 publication Critical patent/JP2014515258A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1382—Adipose-derived stem cells [ADSC], adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2014510832A 2011-05-19 2012-05-18 免疫調節活性を有する細胞集団、その調製方法、及び、その使用 Pending JP2014515258A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11166808.3 2011-05-19
EP11166808 2011-05-19
PCT/EP2012/059313 WO2012156522A1 (en) 2011-05-19 2012-05-18 Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018072015A Division JP6592551B2 (ja) 2011-05-19 2018-04-04 免疫調節活性を有する細胞集団、その調製方法、及び、その使用

Publications (2)

Publication Number Publication Date
JP2014515258A true JP2014515258A (ja) 2014-06-30
JP2014515258A5 JP2014515258A5 (enExample) 2015-07-02

Family

ID=46149436

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014510832A Pending JP2014515258A (ja) 2011-05-19 2012-05-18 免疫調節活性を有する細胞集団、その調製方法、及び、その使用
JP2018072015A Active JP6592551B2 (ja) 2011-05-19 2018-04-04 免疫調節活性を有する細胞集団、その調製方法、及び、その使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018072015A Active JP6592551B2 (ja) 2011-05-19 2018-04-04 免疫調節活性を有する細胞集団、その調製方法、及び、その使用

Country Status (6)

Country Link
US (1) US20140348808A1 (enExample)
EP (1) EP2710122B1 (enExample)
JP (2) JP2014515258A (enExample)
KR (1) KR20140071277A (enExample)
ES (1) ES2487465T1 (enExample)
WO (1) WO2012156522A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014523934A (ja) * 2011-06-14 2014-09-18 コアテツクス アルキルシクロヘキシロール含有非イオン性会合性増粘剤、これらを含む配合物、およびこれらの使用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056972A2 (en) 2009-11-04 2011-05-12 Case Western Reserve University Compositions and methods of treating a t cell mediated disorder
EP3551749B1 (en) 2016-12-07 2023-09-27 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
JP2021531280A (ja) * 2018-03-27 2021-11-18 スミス セラピューティクス インコーポレイテッド 神経変性疾患を処置するためのＣＡＲ−Ｔｒｅｇベースの治療
CN109913415B (zh) * 2019-03-26 2020-05-22 广东先康达生物科技有限公司 Treg细胞的培养液及其培养方法与应用
JP2024532516A (ja) * 2021-09-03 2024-09-05 サンガモ セラピューティクス，インコーポレイテッド Ｍｏｇ結合タンパク質及びその使用
WO2024046355A1 (en) * 2022-09-02 2024-03-07 Medical And Pharmaceutical Industry Technology And Development Center Use of composition including mesenchymal stem cells for alleviating myelofibrosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009508089A (ja) * 2005-08-02 2009-02-26 センテナリ インスティチュート オブ キャンサー メディシン アンド セル バイオロジー 調節性ｔ細胞を同定する方法
WO2010135255A1 (en) * 2009-05-18 2010-11-25 Therakos, Inc. Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases
WO2011048222A1 (en) * 2009-10-23 2011-04-28 Cellerix S.A. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147865A1 (en) * 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells
CA2552891A1 (en) * 2004-01-08 2005-08-04 Regents Of The University Of California Regulatory t cells suppress autoimmunity
JP5925408B2 (ja) 2005-09-23 2016-05-25 タイジェニックス、ソシエダッド、アノニマ、ウニペルソナルＴｉｇｅｎｉｘ Ｓ．Ａ．Ｕ． 免疫調節活性を有する細胞集団、単離方法および使用
EP2050814A1 (en) * 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009508089A (ja) * 2005-08-02 2009-02-26 センテナリ インスティチュート オブ キャンサー メディシン アンド セル バイオロジー 調節性ｔ細胞を同定する方法
WO2010135255A1 (en) * 2009-05-18 2010-11-25 Therakos, Inc. Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases
WO2011048222A1 (en) * 2009-10-23 2011-04-28 Cellerix S.A. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STRAUSS L ET AL.: "Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral", INT J CANCER., vol. 121, no. 11, JPN6016013794, 1 December 2007 (2007-12-01), pages 2473 - 2483, ISSN: 0003298246 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014523934A (ja) * 2011-06-14 2014-09-18 コアテツクス アルキルシクロヘキシロール含有非イオン性会合性増粘剤、これらを含む配合物、およびこれらの使用

Also Published As

Publication number Publication date
KR20140071277A (ko) 2014-06-11
EP2710122B1 (en) 2021-03-31
EP2710122A1 (en) 2014-03-26
JP6592551B2 (ja) 2019-10-16
JP2018134086A (ja) 2018-08-30
ES2487465T1 (es) 2014-08-20
US20140348808A1 (en) 2014-11-27
WO2012156522A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
JP6592551B2 (ja) 免疫調節活性を有する細胞集団、その調製方法、及び、その使用
Badillo et al. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response
EP2561066B1 (en) Adherent stromal cells derived from plancentas of multiple donors and uses thereof
US9011840B2 (en) Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
JP2017165757A (ja) 間葉系間質細胞集団およびそれを作成する方法
US20140154227A1 (en) Cell populations having immunoregulatory activity, method for isolation and uses
JP2018518188A (ja) 細胞療法のための細胞集団を調整するための方法及び装置
JP2013507945A (ja) 免疫調節活性を有する細胞集団、その製造方法及び使用
AU2012255112A1 (en) Mesenchymal stromal cell populations and methods of making same
WO2006107101A1 (ja) 制御性ｔ細胞の製造方法
JP5745419B2 (ja) 細胞、核酸構築物、前記構築物を含む細胞、及び疾患の治療において前記細胞を利用する方法
JP5089389B2 (ja) 移植における免疫応答の予防および治療のための肝臓間質細胞
Kapranov et al. Co-culturing of multipotent mesenchymal stromal cells with autological and allogenic lymphocytes
Brown Maintenance and modification of mesenchymal stromal cell immunosuppressive phenotype
Pittenger et al. Immunological properties of mesenchymal stem cells isolated from bone marrow and umbilical cord
JP2008526891A (ja) 移植された神経幹細胞の免疫防御のための骨髄間質細胞
KR20150102383A (ko) Ex vivo로 조작된 생 자가세포 제조를 위한 자가유래 면역세포 배양방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170720

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171205